A large population-based study found that GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is), two classes of glucose-lowering drugs used in type 2 diabetes, were associated with a significantly reduced risk of Alzheimer’s disease and related dementias (ADRD). These findings suggest potential neuroprotective benefits and highlight drug repurposing as a promising strategy for ADRD prevention.